At the highest dose tested, Vaxcyte’s shot elicited a stronger immune response against 18 of the 20 strains compared with ...

Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a rare form of skin cancer. The FDA’s approval of avelumab ...

Vaxcyte shares rocketed Tuesday after the biotech company delivered "stunning" test results for its pneumococcal vaccine.

Pfizer's recent financial performance shows 14% YoY operational growth excluding COVID sales. Check out more on PFE stock ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

They selected healthcare companies AbbVie (NYSE: ABBV), Merck (NYSE: MRK), and Pfizer (NYSE: PFE). Here's why. Keith Speights (AbbVie): You can count the number of Dividend Kings that operate in ...

Pfizer has not launched any digital treatments ... detailed data showing that its experimental lung cancer therapy beat Merck’s blockbuster Keytruda in a late-stage trial. That study was ...

creating a formidable challenge to Merck and Pfizer, currently the market leaders for this niche. Shares of Pfizer fell almost 3%. Write to Rob Curran at [email protected] About Dow Jones ...

AbbVie is a Dividend King with solid growth prospects. Merck's looming patent cliff isn't as alarming as it might seem. Pfizer offers a high dividend yield and lots of upside potential.

Merck's revenue and earnings continue to grow ... The company is an excellent income stock to buy and hold. Pfizer is a high-yielding stock with a lot of upsides David Jagielski (Pfizer): One ...